(MET) MetLife - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US59156R1086
Stock: Insurance, Annuities, Benefits, Investments
Total Rating 17
Risk 53
Buy Signal -0.32
| Risk 5d forecast | |
|---|---|
| Volatility | 28.7% |
| Relative Tail Risk | 2.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.36 |
| Alpha | -25.57 |
| Character TTM | |
|---|---|
| Beta | 0.836 |
| Beta Downside | 1.377 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.97% |
| CAGR/Max DD | 0.37 |
EPS (Earnings per Share)
Revenue
Description: MET MetLife March 05, 2026
MetLife, Inc. (MET) is a global financial services company. It offers insurance, annuities, employee benefits, and asset management.
The company operates across six segments, including Group Benefits, Retirement and Income Solutions, and various international regions. Its product portfolio includes life, dental, disability, and vision insurance, as well as prepaid legal plans. Insurance companies generate revenue through premiums and investment income.
MetLife also provides diverse annuity products, pension risk transfers, and institutional income annuities. Annuities are financial products that offer a stream of payments, often used for retirement planning.
Further research into MetLifes financial health on platforms like ValueRay could provide deeper insights.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 3.38b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.21 > 1.0 |
| NWC/Revenue: 80.91% < 20% (prev 185.6%; Δ -104.7% < -1%) |
| CFO/TA 0.02 > 3% & CFO 18.11b > Net Income 3.38b |
| Net Debt (-2.70b) to EBITDA (5.72b): -0.47 < 3 |
| Current Ratio: 4.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (665.0m) vs 12m ago -4.72% < -2% |
| Gross Margin: 25.57% > 18% (prev 0.27%; Δ 2530 % > 0.5%) |
| Asset Turnover: 10.73% > 50% (prev 10.35%; Δ 0.38% > 0%) |
| Interest Coverage Ratio: 4.39 > 6 (EBITDA TTM 5.72b / Interest Expense TTM 1.06b) |
Altman Z'' 0.82
| A: 0.08 (Total Current Assets 79.07b - Total Current Liabilities 17.47b) / Total Assets 741.67b |
| B: 0.06 (Retained Earnings 44.29b / Total Assets 741.67b) |
| C: 0.01 (EBIT TTM 4.66b / Avg Total Assets 709.57b) |
| D: 0.04 (Book Value of Equity 26.22b / Total Liabilities 716.25b) |
| Altman-Z'' Score: 0.82 = B |
Beneish M -2.47
| DSRI: 1.47 (Receivables 49.06b/30.77b, Revenue 76.13b/70.13b) |
| GMI: 1.07 (GM 25.57% / 27.36%) |
| AQI: 1.11 (AQ_t 0.89 / AQ_t-1 0.80) |
| SGI: 1.09 (Revenue 76.13b / 70.13b) |
| TATA: -0.02 (NI 3.38b - CFO 18.11b) / TA 741.67b) |
| Beneish M-Score: -2.47 (Cap -4..+1) = BBB |
What is the price of MET shares?
As of March 07, 2026, the stock is trading at USD 71.83 with a total of 3,844,115 shares traded.
Over the past week, the price has changed by -0.33%, over one month by -5.96%, over three months by -7.35% and over the past year by -10.04%.
Over the past week, the price has changed by -0.33%, over one month by -5.96%, over three months by -7.35% and over the past year by -10.04%.
Is MET a buy, sell or hold?
MetLife has received a consensus analysts rating of 4.19.
Therefore, it is recommended to buy MET.
- StrongBuy: 7
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MET price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.9 | 26.6% |
| Analysts Target Price | 90.9 | 26.6% |
MET Fundamental Data Overview March 05, 2026
P/E Trailing = 15.4289
P/E Forward = 7.2939
P/S = 0.6212
P/B = 1.6817
P/EG = 0.5883
Revenue TTM = 76.13b USD
EBIT TTM = 4.66b USD
EBITDA TTM = 5.72b USD
Long Term Debt = 18.62b USD (from longTermDebt, last quarter)
Short Term Debt = 355.0m USD (from shortTermDebt, last quarter)
Debt = 19.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.70b USD (from netDebt column, last quarter)
Enterprise Value = 45.18b USD (47.88b + Debt 19.33b - CCE 22.03b)
Interest Coverage Ratio = 4.39 (Ebit TTM 4.66b / Interest Expense TTM 1.06b)
EV/FCF = 2.50x (Enterprise Value 45.18b / FCF TTM 18.11b)
FCF Yield = 40.07% (FCF TTM 18.11b / Enterprise Value 45.18b)
FCF Margin = 23.78% (FCF TTM 18.11b / Revenue TTM 76.13b)
Net Margin = 4.44% (Net Income TTM 3.38b / Revenue TTM 76.13b)
Gross Margin = 25.57% ((Revenue TTM 76.13b - Cost of Revenue TTM 56.67b) / Revenue TTM)
Gross Margin QoQ = 30.53% (prev 17.40%)
Tobins Q-Ratio = 0.06 (Enterprise Value 45.18b / Total Assets 741.67b)
Interest Expense / Debt = 1.36% (Interest Expense 263.0m / Debt 19.33b)
Taxrate = 26.95% (301.0m / 1.12b)
NOPAT = 3.40b (EBIT 4.66b * (1 - 26.95%))
Current Ratio = 4.53 (Total Current Assets 79.07b / Total Current Liabilities 17.47b)
Debt / Equity = 0.68 (Debt 19.33b / totalStockholderEquity, last quarter 28.40b)
Debt / EBITDA = -0.47 (Net Debt -2.70b / EBITDA 5.72b)
Debt / FCF = -0.15 (Net Debt -2.70b / FCF TTM 18.11b)
Total Stockholder Equity = 28.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.48% (Net Income 3.38b / Total Assets 741.67b)
RoE = 12.01% (Net Income TTM 3.38b / Total Stockholder Equity 28.13b)
RoCE = 9.97% (EBIT 4.66b / Capital Employed (Equity 28.13b + L.T.Debt 18.62b))
RoIC = 7.11% (NOPAT 3.40b / Invested Capital 47.92b)
WACC = 6.70% (E(47.88b)/V(67.21b) * Re(9.0%) + D(19.33b)/V(67.21b) * Rd(1.36%) * (1-Tc(0.27)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.55%
[DCF] Terminal Value 83.88% ; FCFF base≈16.91b ; Y1≈18.12b ; Y5≈22.03b
[DCF] Fair Price = 793.4 (EV 514.61b - Net Debt -2.70b = Equity 517.31b / Shares 652.1m; r=6.70% [WACC]; 5y FCF grow 8.03% → 2.90% )
EPS Correlation: 53.87 | EPS CAGR: 4.91% | SUE: 1.01 | # QB: 1
Revenue Correlation: 40.86 | Revenue CAGR: 11.64% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.49 | Chg7d=-0.003 | Chg30d=-0.016 | Revisions Net=-1 | Analysts=13
EPS current Year (2026-12-31): EPS=9.80 | Chg7d=-0.013 | Chg30d=-0.045 | Revisions Net=-4 | Growth EPS=+11.0% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=10.95 | Chg7d=-0.039 | Chg30d=-0.060 | Revisions Net=+1 | Growth EPS=+11.7% | Growth Revenue=+4.6%
[Analyst] Revisions Ratio: -0.11 (4 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.5% (Discount Rate 9.0% - Earnings Yield 6.5%)
[Growth] Growth Spread = +7.3% (Analyst 9.8% - Implied 2.5%)
P/E Forward = 7.2939
P/S = 0.6212
P/B = 1.6817
P/EG = 0.5883
Revenue TTM = 76.13b USD
EBIT TTM = 4.66b USD
EBITDA TTM = 5.72b USD
Long Term Debt = 18.62b USD (from longTermDebt, last quarter)
Short Term Debt = 355.0m USD (from shortTermDebt, last quarter)
Debt = 19.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.70b USD (from netDebt column, last quarter)
Enterprise Value = 45.18b USD (47.88b + Debt 19.33b - CCE 22.03b)
Interest Coverage Ratio = 4.39 (Ebit TTM 4.66b / Interest Expense TTM 1.06b)
EV/FCF = 2.50x (Enterprise Value 45.18b / FCF TTM 18.11b)
FCF Yield = 40.07% (FCF TTM 18.11b / Enterprise Value 45.18b)
FCF Margin = 23.78% (FCF TTM 18.11b / Revenue TTM 76.13b)
Net Margin = 4.44% (Net Income TTM 3.38b / Revenue TTM 76.13b)
Gross Margin = 25.57% ((Revenue TTM 76.13b - Cost of Revenue TTM 56.67b) / Revenue TTM)
Gross Margin QoQ = 30.53% (prev 17.40%)
Tobins Q-Ratio = 0.06 (Enterprise Value 45.18b / Total Assets 741.67b)
Interest Expense / Debt = 1.36% (Interest Expense 263.0m / Debt 19.33b)
Taxrate = 26.95% (301.0m / 1.12b)
NOPAT = 3.40b (EBIT 4.66b * (1 - 26.95%))
Current Ratio = 4.53 (Total Current Assets 79.07b / Total Current Liabilities 17.47b)
Debt / Equity = 0.68 (Debt 19.33b / totalStockholderEquity, last quarter 28.40b)
Debt / EBITDA = -0.47 (Net Debt -2.70b / EBITDA 5.72b)
Debt / FCF = -0.15 (Net Debt -2.70b / FCF TTM 18.11b)
Total Stockholder Equity = 28.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.48% (Net Income 3.38b / Total Assets 741.67b)
RoE = 12.01% (Net Income TTM 3.38b / Total Stockholder Equity 28.13b)
RoCE = 9.97% (EBIT 4.66b / Capital Employed (Equity 28.13b + L.T.Debt 18.62b))
RoIC = 7.11% (NOPAT 3.40b / Invested Capital 47.92b)
WACC = 6.70% (E(47.88b)/V(67.21b) * Re(9.0%) + D(19.33b)/V(67.21b) * Rd(1.36%) * (1-Tc(0.27)))
Discount Rate = 9.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.55%
[DCF] Terminal Value 83.88% ; FCFF base≈16.91b ; Y1≈18.12b ; Y5≈22.03b
[DCF] Fair Price = 793.4 (EV 514.61b - Net Debt -2.70b = Equity 517.31b / Shares 652.1m; r=6.70% [WACC]; 5y FCF grow 8.03% → 2.90% )
EPS Correlation: 53.87 | EPS CAGR: 4.91% | SUE: 1.01 | # QB: 1
Revenue Correlation: 40.86 | Revenue CAGR: 11.64% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.49 | Chg7d=-0.003 | Chg30d=-0.016 | Revisions Net=-1 | Analysts=13
EPS current Year (2026-12-31): EPS=9.80 | Chg7d=-0.013 | Chg30d=-0.045 | Revisions Net=-4 | Growth EPS=+11.0% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=10.95 | Chg7d=-0.039 | Chg30d=-0.060 | Revisions Net=+1 | Growth EPS=+11.7% | Growth Revenue=+4.6%
[Analyst] Revisions Ratio: -0.11 (4 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.5% (Discount Rate 9.0% - Earnings Yield 6.5%)
[Growth] Growth Spread = +7.3% (Analyst 9.8% - Implied 2.5%)